Praxair Canada Inc., has now gained the necessary approvals to sell its Noxivent brand of inhaled nitric oxide in Canada, thought to be prompted by its latest acquisition.
The Tier One player acquired UK-based business NOxBOX last month, which specialises in manufacturing of inhaled gas delivery and monitoring instruments for the medical market.
Notably, NOxBOX’s NOxBOXiTM system provides intelligent nitric oxide (NOx) delivery for in-hospital use.
The wholly-owned subsidiary’s Noxivent gas is used for the treatment of new-borns up to 34 weeks old, to improve oxygenation in cases of hypoxic respiratory failure.
... to continue reading you must be subscribed
